Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

KALA

Kala Bio Inc

Jan 22 • 04:00PM ET

7.69

Dollar change +0.01
Percentage change 0.13	%

Healthcare • Biotechnology • USA • NASD

Peers: OCUL CLSD EYPT APLS EDIT ALDX ARVN CRVS NSPR

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-12.47	Insider Own	20.09%	Shs Outstand	4.61M	Perf Week	15.64%
Market Cap	35.46M	Forward P/E	-	EPS next Y	-6.21	Insider Trans	47.59%	Shs Float	3.68M	Perf Month	33.51%
Income	-38.96M	PEG	-	EPS next Q	-2.28	Inst Own	39.93%	Short Float	0.69%	Perf Quarter	47.88%
Sales	0.00M	P/S	-	EPS this Y	37.55%	Inst Trans	48.33%	Short Ratio	0.66	Perf Half Y	12.10%
Book/sh	1.49	P/B	5.17	EPS next Y	42.64%	ROA	-67.64%	Short Interest	0.03M	Perf Year	3.64%
Cash/sh	10.67	P/C	0.72	EPS next 5Y	-	ROE	-430.96%	52W Range	4.21 - 8.79	Perf YTD	10.81%
Dividend Est.	-	P/FCF	-	EPS past 5Y	32.60%	ROI	-152.48%	52W High	-12.51%	Beta	-2.06
Dividend TTM	-	Quick Ratio	2.15	Sales past 5Y	-20.99%	Gross Margin	-	52W Low	82.66%	ATR (14)	0.53
Dividend Ex-Date	-	Current Ratio	2.15	EPS Y/Y TTM	70.70%	Oper. Margin	-	RSI (14)	61.19	Volatility	7.94% 8.00%
Employees	43	Debt/Eq	5.40	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	15.00
Option/Short	No / Yes	LT Debt/Eq	2.72	EPS Q/Q	43.33%	Payout	-	Rel Volume	1.95	Prev Close	7.68
Sales Surprise	-	EPS Surprise	20.58%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	38.87K	Price	7.69
SMA20	9.59%	SMA50	13.74%	SMA200	19.55%	Trades		Volume	75,966	Change	0.13%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-30-22	Downgrade	JP Morgan	Neutral → Underweight
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Sep-14-20	Downgrade	Jefferies	Buy → Hold	$10
Jul-23-20	Initiated	Northland Capital	Outperform
Jun-01-20	Resumed	Oppenheimer	Outperform	$21
May-27-20	Reiterated	H.C. Wainwright	Buy	$14 → $17
Mar-09-20	Upgrade	BofA/Merrill	Neutral → Buy
Dec-17-19	Downgrade	BofA/Merrill	Buy → Neutral	$9 → $6
Mar-14-19	Initiated	Jefferies	Buy	$15

Dec-30-24 08:00AM	KALA BIO Announces $10,750,000 Private Placement (GlobeNewswire)
Nov-27-24 08:00AM	KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-12-24 08:00AM	KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-24 08:00AM	KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) -6.35%
Aug-06-24 01:53PM	KALA Stock Earnings: Kala Bio Beats EPS for Q2 2024 (InvestorPlace)
08:00AM	Loading…
08:00AM	KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-27-24 08:00AM	KALA BIO Announces $12,500,000 Private Placement (GlobeNewswire) +40.22%
May-29-24 08:00AM	KALA BIO to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-24 01:13PM	Wall Street Analysts Just Trimmed Price Target for KALA BIO, Inc. (NASDAQ:KALA) (Insider Monkey)
11:17AM	Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks (Insider Monkey)
May-14-24 10:54PM	KALA Stock Earnings: Kala Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-02-24 07:53AM	KALA Stock Earnings: Kala Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
Mar-29-24 08:00AM	KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-26-24 08:00AM	KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference (GlobeNewswire)
08:00AM	Loading…
Feb-06-24 08:00AM	KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-19-24 04:01PM	KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.91%
Nov-13-23 08:00AM	KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-20-23 04:01PM	KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-23 08:00AM	KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -11.58%
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-04-23 08:11AM	Kala Pharma: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-02-23 04:01PM	KALA BIO to Participate in Upcoming Investor Conferences in August (GlobeNewswire) -5.28%
08:00AM	Kala Pharmaceuticals Announces Name Change to KALA BIO (GlobeNewswire)
Jul-19-23 04:01PM	Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-23-23 04:01PM	Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-23 08:00AM	Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire) +11.17%
May-11-23 12:20PM	10 Best Stocks to Buy for a Quick Return (Insider Monkey) +15.57%
May-09-23 08:07AM	Kala Pharma: Q1 Earnings Snapshot (AP Finance)
08:00AM	Loading…
08:00AM	Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-28-23 08:00AM	Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED (GlobeNewswire)
Apr-14-23 12:49PM	Regulus (RGLS) Surges on Enrollment Completion for RGLS8429 (Zacks) -6.78%
Apr-13-23 11:22AM	Biotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News (Zacks)
11:10AM	KALA Up on Fast Track Designation to Lead Ocular Candidate (Zacks)
Apr-12-23 08:00AM	Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect (GlobeNewswire)
Apr-05-23 05:50PM	Kala Pharmaceuticals (KALA) Dips More Than Broader Markets: What You Should Know (Zacks)
Apr-04-23 01:32PM	CRISPR (CRSP) & Vertex Complete BLA Submission for Exa-Cel (Zacks)
01:16PM	Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study (Zacks)
Mar-30-23 05:50PM	Kala Pharmaceuticals (KALA) Stock Sinks As Market Gains: What You Should Know (Zacks)
Mar-29-23 08:00AM	Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor (GlobeNewswire) -5.73%
Mar-28-23 11:04AM	Amicus (FOLD) Gets Pompe Disease Treatment Approval in Europe (Zacks)
Mar-27-23 08:00AM	Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED (GlobeNewswire)
Mar-24-23 09:55AM	Wall Street Analysts Predict a 213.6% Upside in Kala Pharma (KALA): Here's What You Should Know (Zacks) +6.43%
Mar-23-23 11:09AM	Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders (Zacks)
Mar-22-23 09:30AM	Kala Pharmaceuticals (KALA) Recently Broke Out Above the 200-Day Moving Average (Zacks) -6.47%
07:37AM	Zacks Industry Outlook Highlights CRISPR Therapeutics, Ligand Pharmaceuticals, Theseus Pharmaceuticals and Kala Pharmaceuticals (Zacks)
Mar-20-23 12:04PM	Axsome (AXSM) Stock Up 17% in Six Months: Here's Why (Zacks) -8.95%
09:30AM	Wall Street Bulls Look Optimistic About Kala Pharma (KALA): Should You Buy? (Zacks)
Mar-17-23 02:54PM	Sarepta (SRPT) Stock Down, FDA to Hold Panel Meet for SRP-9001 (Zacks)
Mar-09-23 09:30AM	Kala Pharmaceuticals (KALA) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks) -13.76%
Mar-08-23 04:01PM	Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire) +15.95%
09:55AM	How Much Upside is Left in Kala Pharma (KALA)? Wall Street Analysts Think 143.91% (Zacks)
Mar-06-23 12:33PM	KALA Q4 Loss Wider Than Expected, Pipeline Remains in Focus (Zacks) +33.37%
Mar-03-23 03:02PM	Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating (Investor's Business Daily) +64.70%
08:00AM	Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-02-23 09:30AM	Wall Street Analysts Think Kala Pharma (KALA) Is a Good Investment: Is It? (Zacks) +6.72%
Feb-22-23 05:50PM	Kala Pharmaceuticals (KALA) Flat As Market Sinks: What You Should Know (Zacks) +5.21%
Feb-14-23 05:45PM	Kala Pharmaceuticals (KALA) Gains As Market Dips: What You Should Know (Zacks)
Feb-08-23 05:45PM	Kala Pharmaceuticals (KALA) Stock Moves -0.66%: What You Should Know (Zacks) -13.42%
Feb-01-23 04:25PM	7 Top Short-Squeeze Candidates to Watch in February (InvestorPlace)
Jan-19-23 09:30AM	Kala Pharma (KALA) Is Considered a Good Investment by Brokers: Is That True? (Zacks) -6.29%
Jan-17-23 10:00AM	Best Momentum Stocks to Buy for January 17th (Zacks)
Dec-30-22 12:02PM	Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment (MarketWatch) +53.58%
02:59AM	Southwest, Tesla, Mesa Air fall premarket; Kala Pharmaceuticals soars (Investing.com)
Dec-29-22 09:55AM	Wall Street Analysts Predict a 268% Upside in Kala Pharma (KALA): Here's What You Should Know (Zacks) +99.04%
Dec-28-22 11:13AM	Kala Pharmaceuticals (KALA) Up as FDA Accepts IND for KPI-012 (Zacks) +218.37%
09:44AM	Biotech Stock Kala Surges After Clinical Trial Announcement (The Wall Street Journal)
06:48AM	Kala Pharmaceuticals stock rockets nearly 300% after FDA OKs IND application for PCED treatment (MarketWatch)
Dec-27-22 04:01PM	Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED (GlobeNewswire)
Dec-20-22 10:03AM	Entrada (TRDA) Down on Regulatory Update for DMD Candidate (Zacks)
09:06AM	bluebird's (BLUE) SCD Studies Clinical Hold Lifted by the FDA (Zacks)
Dec-07-22 09:55AM	Here's Why Kala Pharma (KALA) Looks Ripe for Bottom Fishing (Zacks)
Dec-06-22 01:22PM	Cigna (CI) Focuses on Enhancing Pharmacy Offerings in 2023 (Zacks)
Nov-28-22 04:02PM	Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (GlobeNewswire)
04:01PM	Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing (GlobeNewswire)
Nov-10-22 06:26AM	Kala Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-08-22 08:00AM	Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-22 07:30AM	Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors (GlobeNewswire)
Oct-20-22 07:30AM	Kala Pharmaceuticals Announces Reverse Stock Split (GlobeNewswire) -14.97%
Sep-06-22 08:00AM	Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-19-22 04:01PM	Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -6.45%
Aug-18-22 04:01PM	Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock (GlobeNewswire)
Aug-11-22 09:41AM	Kala Pharma Stops Working On Certain Preclinical Programs, Extends Cash Runway Into 2024 (Benzinga) -5.75%
08:15AM	Kala Pharmaceuticals (KALA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-09-22 09:35AM	AquaBounty Technologies, Inc. (AQB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-08-22 09:00AM	Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call (GlobeNewswire)
Aug-04-22 04:01PM	Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August (GlobeNewswire)
Jul-22-22 04:01PM	Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.64% -5.77%
Jul-11-22 08:00AM	Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc (GlobeNewswire) -5.31%
Jul-06-22 12:00PM	Kala Pharma (KALA) Moves to Buy: Rationale Behind the Upgrade (Zacks) +5.81%
Jun-17-22 04:01PM	Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +8.57% -5.78%
Jun-02-22 08:00AM	Kala Pharmaceuticals to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-26-22 11:03AM	The Petri Dish: NIH gives $68M to Pfizer-partnered AI startup (American City Business Journals) -13.20%
May-23-22 06:29AM	This Biopharma Stock Surges After Offloading Its Ophthalmic Eye Drop Portfolio (Benzinga) -6.30%
12:01AM	Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc. (GlobeNewswire)
May-16-22 08:15AM	Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +8.47%
07:00AM	Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-12-22 07:15AM	Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)

KALA BIO, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kharabi Darius	CHIEF BUSINESS OFFICER	Jan 06 '25	Sale	7.63	2,021	15,420	67,807	Jan 07 08:14 PM
Brazzell Romulus K	SEE REMARKS	Jan 06 '25	Sale	7.63	2,446	18,663	92,418	Jan 07 08:13 PM
Iwicki Mark T	CHIEF EXECUTIVE OFFICER	Jan 06 '25	Sale	7.63	5,779	44,094	280,076	Jan 07 08:12 PM
Reumuth Mary	CHIEF FINANCIAL OFFICER	Jan 06 '25	Sale	7.63	1,706	13,017	68,581	Jan 07 08:12 PM
Mark T Iwicki	Officer	Jan 06 '25	Proposed Sale	7.63	5,779	44,079		Jan 06 08:06 PM
BAKER BROS. ADVISORS LP	10% Owner	Dec 30 '24	Buy	6.44	310,559	2,000,000	1,083,398	Dec 31 04:00 PM
Bazemore Todd	SEE REMARKS	Jun 26 '24	Sale	4.75	4,653	22,102	83,040	Jun 27 08:00 PM
Kharabi Darius	CHIEF BUSINESS OFFICER	Jun 26 '24	Sale	4.75	5,158	24,500	59,728	Jun 27 08:00 PM
Reumuth Mary	CHIEF FINANCIAL OFFICER	Jun 26 '24	Sale	4.75	4,163	19,774	60,187	Jun 27 08:00 PM
Iwicki Mark T	CHIEF EXECUTIVE OFFICER	Jun 26 '24	Sale	4.75	15,168	72,048	263,755	Jun 27 08:00 PM
Brazzell Romulus K	SEE REMARKS	Jun 26 '24	Sale	4.75	5,489	26,073	83,982	Jun 27 08:00 PM
Bazemore Todd	SEE REMARKS	May 31 '24	Sale	6.09	2,093	12,746	87,693	Jun 03 08:00 PM
Kharabi Darius	CHIEF BUSINESS OFFICER	May 31 '24	Sale	6.09	231	1,407	64,886	Jun 03 08:00 PM
Reumuth Mary	CHIEF FINANCIAL OFFICER	May 31 '24	Sale	6.09	1,786	10,877	64,350	Jun 03 08:00 PM
Brazzell Romulus K	SEE REMARKS	May 31 '24	Sale	6.09	2,002	12,192	89,471	Jun 03 08:00 PM
Iwicki Mark T	CHIEF EXECUTIVE OFFICER	May 31 '24	Sale	6.09	7,392	45,017	278,923	Jun 03 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KALA

Kala Bio Inc

Upgrade your FINVIZ experience